<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730390</url>
  </required_header>
  <id_info>
    <org_study_id>009-PPA-1001</org_study_id>
    <nct_id>NCT02730390</nct_id>
  </id_info>
  <brief_title>Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing Surveillance</brief_title>
  <official_title>Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical, Inc., Philippines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical, Inc., Philippines</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this post marketing surveillance (PMS) is to determine the safety&#xD;
      and efficacy of probucol in lowering the level of serum cholesterol in the blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This nationwide post marketing surveillance targets to recruit a total of 3,000 patients with&#xD;
      hyperlipidemia. Duration of treatment is 60 days. The usual starting dose for Lorelco is 500&#xD;
      mg administered daily, divided into two (2) doses (250mg BID) and given after meals. The dose&#xD;
      may be adjusted according to the patient's age and condition. Lipid serum test will be&#xD;
      obtained at Day 0 (Baseline). In subjects requiring antihyperlipidemics that fulfill the&#xD;
      inclusion criteria, Lorelco 250 BID will be started. There will be 2 follow-up visits after&#xD;
      baseline on Day 30 and Day 60. Both lipid serum tests and ECG will be done on these 2&#xD;
      follow-up visits. During each visit the investigator will assess the subject's vital signs&#xD;
      and symptoms and check for any adverse events.&#xD;
&#xD;
      The primary outcome of measure is the percentage reduction or increase in total cholesterol&#xD;
      and triglycerides from baseline values at Week 0 to Week 4 and Week 8 using the following&#xD;
      scale:&#xD;
&#xD;
      Total Cholesterol Triglycerides&#xD;
&#xD;
        1. Markedly reduced&#xD;
&#xD;
        2. Moderately reduced&#xD;
&#xD;
        3. Slightly reduced&#xD;
&#xD;
        4. Unchanged&#xD;
&#xD;
        5. Increased Reduction of ≥ 15% Reduction of ≥ 10% but &lt; 15% Reduction of ≥ 5% but &lt; 10%&#xD;
           Change of &lt; 5% Increase of ≥ 5% Reduction of ≥ 30% Reduction of ≥ 20% but &lt; 30%&#xD;
           Reduction of ≥ 10% but &lt; 20% Change of &lt; 10% Increase of ≥ 10% The percentage change on&#xD;
           the last week of treatment will be the final evaluation.&#xD;
&#xD;
      The secondary outcome is measured by the changes in symptoms and vital signs. Using the&#xD;
      following scale:&#xD;
&#xD;
        1. Markedly Improved&#xD;
&#xD;
        2. Improved&#xD;
&#xD;
        3. Slightly Improved&#xD;
&#xD;
        4. Unchanged&#xD;
&#xD;
        5. Aggravated&#xD;
&#xD;
        6. Unknown (not assessable)&#xD;
&#xD;
      Safety will be measured by the incidence of adverse events to be collected.&#xD;
&#xD;
      Overall efficacy and safety will be evaluated to assess the usefulness of Lorelco using the&#xD;
      following scale:&#xD;
&#xD;
        1. Very useful&#xD;
&#xD;
        2. Useful&#xD;
&#xD;
        3. Somewhat useful&#xD;
&#xD;
        4. Not useful&#xD;
&#xD;
        5. Unfavorable&#xD;
&#xD;
        6. Unknown (not assessable)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - Improvement in serum lipids.</measure>
    <time_frame>values will be calculated at Day 30</time_frame>
    <description>Percentage changes in total cholesterol and triglycerides from baseline (Day 0) values will be calculated at Day 30 and Day 60.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Improvement in serum lipids.</measure>
    <time_frame>values will be calculated at Day 60</time_frame>
    <description>Percentage changes in total cholesterol and triglycerides from</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Changes in symptoms and vital signs.</measure>
    <time_frame>overall 60 days</time_frame>
    <description>Assessed by investigator using following scale:&#xD;
Markedly Improved&#xD;
Improved&#xD;
Slightly Improved&#xD;
Unchanged&#xD;
Aggravated&#xD;
Unknown (not assessable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Overall Safety will be evaluated to assess the usefulness of the study drug</measure>
    <time_frame>overall 60 days</time_frame>
    <description>Check for any adverse event and assess the usefulness</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3087</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Probucol Tablets</arm_group_label>
    <description>Target is 3,000 patients in the Philippines diagnosed with hyperlipidemia (including familial hypercholesterolemia and xanthoma).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 3,000 patients in the Philippines with hyperlipidemia (including familial&#xD;
        hypercholesterolemia and xanthoma).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosed with hyperlipidemia including familial hypercholesterolemia and xanthoma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

